Cancer Treatment in India

The drug supply is the substantive reason. A course of targeted therapy that costs six figures a year in the United States or Europe can cost a fraction of that in India, because the same molecule is made locally. For a patient on maintenance therapy for two years, that is not a discount — it is the difference between finishing the protocol and stopping early.

The second reason is that staging and treatment are not separated by months. PET-CT, biopsy and a tumour board review typically happen inside a week, and the first cycle or the surgical date follows. In systems where each of those steps carries its own wait, the tumour has moved before treatment starts.

Third, the tumour board model is normal here rather than exceptional. A surgical oncologist, a medical oncologist, a radiation oncologist and a pathologist reviewing your case together produces a better plan than any one of them alone — and it is a reasonable thing to ask a hospital to confirm it does before you commit.

What travel does not fix: cancer treatment is long. If your protocol is six months of chemotherapy plus six weeks of daily radiation, you are either living in India for that period or splitting care between two countries — which is workable, but only if it is planned deliberately with both teams rather than improvised halfway through.

There is no such thing as a cancer success rate, and a hospital advertising one should make you cautious. Outcomes are reported per cancer, per stage, and usually as five-year survival — early-stage breast or thyroid cancer and advanced pancreatic cancer are not on the same scale, and no hospital changes that.

What a treating centre genuinely affects is narrower but real: whether staging was accurate, whether the surgical margins were clear, whether the radiation plan spared the tissue it should have, whether the full protocol was completed on schedule, and how quickly complications were caught. Those are the things to ask about.

Useful questions for the oncologist reviewing your file: what is the realistic goal here — cure, remission, or control? What does the published survival data say for this stage? What is the plan if the first-line protocol does not respond? An oncologist who answers all three plainly is worth more than a brochure with a percentage on it.